Hot Features
프리미엄
무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol-Myers Squibb”) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as...
Levi & Korsinsky is investigating the Board of Directors of Amylin Pharmaceuticals, Inc. (“Amylin” or the “Company”) (Nasdaq: AMLN) for possible breaches of fiduciary duty and...
Block & Leviton LLP Investigates Amylin Pharmaceuticals, Inc. for Possible Breaches of Fiduciary Duties in Connection with Its Proposed Merger with Bristol-Myers Squibb Company PR...
Bristol-Myers Squibb Company (NYSE: BMY) is commencing today, through its wholly owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding...
Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Amylin Pharmaceuticals, Inc. PR Newswire DALLAS, July 9, 2012 DALLAS, July 9, 2012 /PRNewswire/...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Amylin Pharmaceuticals, Inc (“Amylin” or the “Company”...
Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc. PR Newswire BALA CYNWYD, Pa., July 3, 2012 BALA CYNWYD, Pa., July 3, 2012 /PRNewswire/ -- Law office of...
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/amln) is investigating potential claims against the board of directors of Amylin Pharmaceuticals, Inc. (“Amylin” or the “Company”...
Levi & Korsinsky is investigating the Board of Directors of Amylin Pharmaceuticals, Inc. (“Amylin” or the “Company”) (Nasdaq: AMLN) for possible breaches of fiduciary duty and...
Harwood Feffer LLP Announces Investigation of Amylin Pharmaceuticals, Inc. PR Newswire NEW YORK, July 2, 2012 NEW YORK, July 2, 2012 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
